FDA Approves New Hormonal IUD from Actavis and Medicines360
For Immediate Release
February 27, 2015
WASHINGTON, DC— The Association of Reproductive Health Professionals (ARHP) enthusiastically supports the FDA’s approval of LILETTA™, a new levonorgestrel-releasing intrauterine system developed by Actavis and Medicines360. The partnership between these two organizations is based on a commitment to reducing barriers related to cost and insurance coverage for women seeking highly-effective, reversible contraception. In addition to being commercially available in the United States, LILETTA will be offered at reduced cost to public health clinics enrolled in the 340B Drug Pricing Program.
“On behalf of the 12,000 reproductive health professionals represented by ARHP, I am delighted to congratulate Actavis and Medicines360 on the FDA approval of LILETTA” said Wayne C. Shields, president and CEO of ARHP. “Our members very much share your vision and support the importance of providing effective, safe, and affordable medicines to all women, regardless of socioeconomic status. The launch of LILETTA marks an important advance in contraceptive access and reproductive agency for women across the United States.”
LILETTA is not yet available for ordering. For more information on product availability, distribution, and training, please visit http://medicines360.org.
The Association of Reproductive Health Professionals (ARHP) is the leading
source for trusted medical education and information on reproductive and sexual
health. ARHP educates health care providers, informs consumers, and helps shape
public policy. ARHP is a non-profit membership association composed of highly
qualified and committed experts in reproductive health. ARHP members are health
professionals in clinical practice, education, research, and advocacy and they
include physicians, nurse practitioners, physician assistants, nurse midwives,
researchers, educators, pharmacists, and other professionals in reproductive
health. To learn more, visit: http://www.arhp.org.